EUVIMEDEUVIMED entdecken
Open Access

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

Rodrigo A Toledo, Camilo Jimenez iD, Gustavo Armaiz-Pena, Carlota Arenillas, Jaume Capdevila, Patricia L M Dahia iD

Endocrine Reviews · 04.03.2023 · 44 (2) · 312-322

DOI: 10.1210/endrev/bnac025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 27.10.2022. Verfasst von Rodrigo A Toledo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal and Endocrine Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Sp…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Miguel Servet-I.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumors driven by deficiency of the VHL gene product, which is involved in degradation of the hypoxia-inducible factor subunit 2 alpha (HIF2α), are natural candidates for targeted inhibition of this pathway. Belzutifan, a highly specific and well-tolerated HIF2α inhibitor, recently received FDA approval for the treatment of nonmetastatic renal cell carcinomas, pancreatic neuroendocrine tumors, and central nervous system hemangioblastomas from patients with von Hippel–Lindau disease, who carry VHL germline mutations. Such approval is a milestone in oncology; however, the full potential, and limitations, of HIF2α inhibition in the clinic are just starting to be explored. Here we briefly recapitulate the molecular rationale for HIF2α blockade in tumors and review available preclinical and clinical data, elaborating on mutations that might be particularly sensitive to this approach. We also outline some emerging mechanisms of intrinsic and acquired resistance to HIF2α inhibitors, including acquired mutations of the gatekeeper pocket of HIF2α and its interacting partner ARNT. Lastly, we propose that the high efficacy of belzutifan observed in tumors with genetically driven hypoxia caused by VHL mutations suggests that a focus on other mutations that similarly lead to HIF2α stabilization, such as those occurring in neuroendocrine tumors with disruptions in the tricarboxylic acid cycle (SDHA/B/C/D, FH, MDH2, IDH2), HIF hydroxylases (EGLN/PHDs), and the HIF2α-encoding gene, EPAS1, are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansTumor HypoxiaHypoxiaEndothelial PAS Domain-Containing Protein 1Indenes

Stichwörter der Autor:innen

HIF2VHLbelzutifancancerhypoxiahypoxia-inducible factorinhibitormutationneuroendocrine tumorparagangliomapheochromocytomapseudohypoxiaresistancesensitivitytargeted therapy

Substanzen

Endothelial PAS Domain-Containing Protein 1belzutifanIndenes

Autor:innen und Institutionen

  • Gastrointestinal and Endocrine Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.
  • Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, 08035 Barcelona, Spain.
  • Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA.

ORCID-Profile: Camilo Jimenez, Patricia L M Dahia

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Miguel Servet-I
  • Institute of Health Carlos III
  • Ministry of Economy
  • Consorcio Centro de Investigación Biomédica en Red de Cáncer
  • CIBERONC
  • Hayes Distinguished Chair in Oncology, NIH-NIGMS

Zitieren

APA

Toledo, R. A., Jimenez, C., Armaiz-Pena, G., Arenillas, C., Capdevila, J., & Dahia, P. L. M. (2023). Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocrine Reviews, 44(2), 312-322. https://doi.org/10.1210/endrev/bnac025

Vancouver

Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocrine Reviews. 2023;44(2):312-322. doi:10.1210/endrev/bnac025

BibTeX
@article{Toledo2023,
  author = {Toledo, Rodrigo A and Jimenez, Camilo and Armaiz-Pena, Gustavo and Arenillas, Carlota and Capdevila, Jaume and Dahia, Patricia L M},
  title = {Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia},
  journal = {Endocrine Reviews},
  year = {2023},
  volume = {44},
  number = {2},
  pages = {312--322},
  doi = {10.1210/endrev/bnac025}
}
Kostenlos starten →